Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001311 · ClinicalTrials.gov registry record · Phase 2

Modified Intraocular Lens to Reduce Eye Inflammation After Cataract Surgery in Uveitis Patients

A Phase 2 study, sponsored by National Eye Institute (NEI).

Completed
Registry status
Phase 2
Development phase
80
Enrollment target

NCT00001311 is a Phase 2 study that has completed, run by National Eye Institute (NEI). The registered enrollment target is 80 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001311, a Phase 2 study, has completed, sponsored by National Eye Institute (NEI).

COMPLETED
Registry status
Phase 2
Development phase
80 participants
Enrollment target

Study Summary

This study will test the effectiveness of an intraocular lens treated with heparin in reducing or preventing inflammation after cataract surgery in patients with uveitis. Patients with uveitis (inflammatory eye disease) often develop cataracts (clouding of the lens of the eye) that can impair eyesight. Cataracts can be removed surgically, and this is usually done when poor vision interferes with adequate daily functioning, or when the lens becomes too cloudy to evaluate the level of eye inflammation in uveitis-information needed to adjust medication dosages. After surgery, vision is corrected with special eyeglasses, contact lenses, or intraocular lenses (IOL). IOLs are small, plastic artificial lenses permanently placed inside the eye. Patients with uveitis who require cataract surgery and whose eye inflammation has been controlled by medicine for at least 3 months may be eligible for this study. Those enrolled in the study will be randomly assigned to one of two treatment groups: one group will have a standard IOL implanted during cataract surgery; the other will receive a heparin-treated IOL. Before surgery, patients will undergo standard preoperative tests, including chest X-ray, electrocardiogram, blood tests and urinalysis, as well as an eye examination that includes photography of the cornea, iris and retina. Additional tests and examinations to be done at the start of the study and at periodic follow-up visits for about 1 year may include: fluorescein angiography to evaluate the blood vessels of the retina; specular microscopy to examine the surface of the IOL; cell and flare measurements to evaluate inflammation, and ultrasound to examine the back of the eye.

Interventions

  • DEVICE heparin-surface modified intraocular lens

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 1992-04
Est. Completion 2001-02
Phase Phase 2

Sponsor

National Eye Institute (NEI)

221 total trials

What the Registry Record Tells You About NCT00001311

The ClinicalTrials.gov registry entry for NCT00001311 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which heparin-surface modified intraocular lens is the first listed.

NCT00001311 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00001311 about?

NCT00001311 is a clinical study titled "Modified Intraocular Lens to Reduce Eye Inflammation After Cataract Surgery in Uveitis Patients". This study will test the effectiveness of an intraocular lens treated with heparin in reducing or preventing inflammation after cataract surgery in patients with uveitis. Patients with uveitis (inflammatory eye disease) often develop cataracts (clouding of the lens of the eye) that can impair eyesi...

What is the current status of trial NCT00001311?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 1992-04. Estimated completion is 2001-02.

What interventions are being tested in trial NCT00001311?

The interventions under investigation include: heparin-surface modified intraocular lens (DEVICE).

Who is sponsoring clinical trial NCT00001311?

This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.